SPTXSeaport Therapeutics Inc.

$17.72
$0.60
(3.50%)
Today
Closed $17.72
$0.00
(0.00%)
After Hours
Updated: 04:10 PM EDT
Mkt Cap$916.44M
Vol129,075.00
55

Bullish Sentiment

How do you feel about SPTX?

News
all
press releases
PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo in Healthy Volunteers
PureTech Health plc (LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, notes that its Founded Entity, Seaport Therapeutics, announced positive data from the multiple-ascending dose (MAD...
Business Wire
News Placeholder
More News
News Placeholder
Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
Seaport Therapeutics, Inc., (Nasdaq: SPTX) (Seaport or the Company), a clinical-stage therapeutics company that is inventing and developing novel neuropsychiatric medicines, today announced financial results for the first quarter of 2026 and highlighted recent corporate and clinical progress. The...
Business Wire
News Placeholder
Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo in Healthy Volunteers
Seaport Therapeutics, Inc., (Nasdaq: SPTX) (Seaport or the Company), a clinical-stage therapeutics company that is inventing and developing novel neuropsychiatric medicines, today announced positive data from the multiple-ascending dose (MAD) portion of its Phase 1 proof-of-concept clinical trial...
Business Wire
News Placeholder
Seaport Therapeutics to Participate in Two Upcoming Investor Conferences
Seaport Therapeutics, Inc., (Nasdaq: SPTX) (Seaport or the Company), a clinical-stage therapeutics company that is inventing and developing novel neuropsychiatric medicines, today announced that members of its management team will participate in the following upcoming investor conferences: Goldman...
Business Wire
News Placeholder
Seaport Therapeutics Announces Pricing of Upsized Initial Public Offering
Seaport Therapeutics, Inc., (Nasdaq: SPTX) (Seaport or the Company), a clinical-stage therapeutics company that is inventing and developing neuropsychiatric medicines, today announced the pricing of...
Business Wire
<
...
1
>

Advertisement|Remove ads.